Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Account Payables (2021 - 2025)

Historic Change in Account Payables for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to -$2.7 million.

  • Kiniksa Pharmaceuticals International's Change in Account Payables fell 39945.12% to -$2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 million, marking a year-over-year decrease of 12800.89%. This contributed to the annual value of -$6.3 million for FY2024, which is 191729.11% down from last year.
  • As of Q3 2025, Kiniksa Pharmaceuticals International's Change in Account Payables stood at -$2.7 million, which was down 39945.12% from $6.9 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Change in Account Payables peaked at $7.2 million during Q4 2023, and registered a low of -$6.5 million during Q1 2023.
  • Its 5-year average for Change in Account Payables is $300105.3, with a median of $72000.0 in 2021.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Change in Account Payables soared by 247200.0% in 2022 and then plummeted by 52957.1% in 2023.
  • Kiniksa Pharmaceuticals International's Change in Account Payables (Quarter) stood at $250000.0 in 2021, then surged by 2472.0% to $6.4 million in 2022, then grew by 12.5% to $7.2 million in 2023, then crashed by 186.87% to -$6.3 million in 2024, then skyrocketed by 56.59% to -$2.7 million in 2025.
  • Its Change in Account Payables stands at -$2.7 million for Q3 2025, versus $6.9 million for Q2 2025 and $62000.0 for Q1 2025.